Aliases & Classifications for Keratosis

MalaCards integrated aliases for Keratosis:

Name: Keratosis 12 41 14 69
Actinic Keratosis 69
Hyperkeratosis 69

Classifications:



External Ids:

Disease Ontology 12 DOID:161
MeSH 41 D007642
NCIt 46 C34747
SNOMED-CT 64 254666005

Summaries for Keratosis

Disease Ontology : 12 A skin disease characterized_by growth of keratin on the skin or mucous membranes.

MalaCards based summary : Keratosis, also known as actinic keratosis, is related to keratosis follicularis spinulosa decalvans and keratosis follicularis spinulosa decalvans, x-linked, and has symptoms including trichorrhexis invaginata, pruritus and exanthema. An important gene associated with Keratosis is MBTPS2 (Membrane Bound Transcription Factor Peptidase, Site 2), and among its related pathways/superpathways are Developmental Biology and Keratinization. The drugs Aminolevulinic acid and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and kidney, and related phenotypes are cellular and growth/size/body region

Wikipedia : 72 Keratosis (from keratinocyte, the prominent cell type in the epidermis, and -osis, abnormal) is a growth... more...

Related Diseases for Keratosis

Diseases related to Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 247)
# Related Disease Score Top Affiliating Genes
1 keratosis follicularis spinulosa decalvans 34.1 LRP1 MBTPS2 SAT1
2 keratosis follicularis spinulosa decalvans, x-linked 34.1 MBTPS2 SAT1
3 keratosis, seborrheic 33.7 FGFR3 KRT10 KRT17 PIK3CA
4 actinic keratosis 33.6 CDKN2A KRT17 TP53
5 mal de meleda 32.3 KRT9 SERPINB7 SLURP1
6 epidermodysplasia verruciformis 32.1 FLG KRT1 KRT10
7 striate palmoplantar keratoderma 31.7 CTSC KRT1 KRT10 SERPINB7
8 palmoplantar keratosis 31.5 CTSC GJB2 KRT1 KRT10 KRT9 SERPINB7
9 palmoplantar keratoderma, epidermolytic 31.5 KRT1 KRT17 KRT9
10 dermatosis papulosa nigra 31.5 FGFR3 PIK3CA
11 white sponge nevus 1 31.1 KRT1 KRT10 KRT9
12 palmoplantar keratoderma, nonepidermolytic 30.9 CTSC FLG KRT1 KRT10 KRT9
13 lichen planus 30.2 FLG IVL KRT10 TP53
14 porokeratosis 30.1 FGFR3 FLG IVL
15 acanthoma 30.0 KRT1 KRT10 KRT9
16 basal cell carcinoma 29.9 CDKN2A IVL KRT10 KRT17 TP53
17 keratoacanthoma 29.8 FLG KRT10 KRT17 TP53
18 discoid lupus erythematosus 29.8 FLG IVL KRT10
19 large cell acanthoma 29.5 KRT10 KRT17
20 oral squamous cell carcinoma 29.4 CDKN2A KRT17 TP53
21 psoriasis 29.2 FLG IVL KRT1 KRT10 KRT17
22 ichthyosis 29.1 FLG GJB2 KRT1 KRT10 MBTPS2
23 myeloma, multiple 29.1 CDKN2A FGFR3 TP53
24 epidermolytic hyperkeratosis 28.7 FLG KRT1 KRT10 KRT17 KRT9
25 papilloma 28.6 CDKN2A FGFR3 FLG IVL KRT1 KRT10
26 congenital ichthyosiform erythroderma 28.6 FLG IVL KRT1 KRT10 KRT9
27 keratosis pilaris atrophicans 12.3
28 inverted follicular keratosis 12.3
29 keratosis linearis with ichthyosis congenita and sclerosing keratoderma 12.2
30 keratosis follicularis, dwarfism, and cerebral atrophy 12.2
31 keratosis follicularis spinulosa decalvans, autosomal dominant 12.1
32 vulvar seborrheic keratosis 12.0
33 inflamed seborrheic keratosis 12.0
34 keratosis palmoplantaris striata iii 11.9
35 keratosis palmoplantaris striata ii 11.9
36 darier-white disease 11.9
37 keratosis palmaris et plantaris with clinodactyly 11.8
38 keratosis, familial actinic 11.8
39 keratosis, focal palmoplantar and gingival 11.8
40 onychogryposis, pedal, with keratosis plantaris and coarse hair 11.8
41 vulvar inverted follicular keratosis 11.8
42 circumscribed disseminated keratosis jadassohn lew type 11.8
43 keratosis palmoplantaris adenocarcinoma of the colon 11.8
44 papillon-lefevre syndrome 11.6
45 palmoplantar keratoderma, punctate type ia 11.6
46 haim-munk syndrome 11.5
47 tyrosinemia, type ii 11.5
48 focal palmoplantar and gingival keratoderma 11.5
49 punctate palmoplantar keratoderma 11.4
50 palmoplantar keratoderma i, striate, focal, or diffuse 11.2

Comorbidity relations with Keratosis via Phenotypic Disease Network (PDN):


Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Keratosis, Seborrheic

Graphical network of the top 20 diseases related to Keratosis:



Diseases related to Keratosis

Symptoms & Phenotypes for Keratosis

UMLS symptoms related to Keratosis:


trichorrhexis invaginata, pruritus, exanthema

MGI Mouse Phenotypes related to Keratosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.9 SAT1 SLURP1 ATP2A2 TP53 CDKN2A CTSC
2 growth/size/body region MP:0005378 9.73 SAT1 SLURP1 ATP2A2 TP53 CDKN2A CTSC
3 integument MP:0010771 9.36 SLURP1 ATP2A2 TP53 CDKN2A CTSC FGFR3

Drugs & Therapeutics for Keratosis

Drugs for Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 203)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
3
Fluorouracil Approved Phase 4,Phase 3,Early Phase 1 51-21-8 3385
4
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 1 15307-86-5 3033
5
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
6
Alginic acid Approved, Experimental, Investigational Phase 4 9005-32-7
7
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
8
Ethanol Approved Phase 4,Phase 2 64-17-5 702
9
Clobetasol Approved, Investigational Phase 4 25122-41-2, 25122-46-7 5311051 32798
10
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
11
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
12
Petrolatum Approved, Investigational Phase 4,Phase 2,Early Phase 1 8009-03-8
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
14
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 69-72-7 338
15
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2 104987-11-3 445643 439492
16
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
17
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
18
Menthol Approved Phase 4 2216-51-5 16666
19
Azathioprine Approved Phase 4 446-86-6 2265
20
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
21
Mycophenolic acid Approved Phase 4 24280-93-1 446541
22
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 68-26-8, 11103-57-4 445354
23
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 10883523 5280795 6221
24
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
25
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 1406-16-2
26 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1
28 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
30 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1
31 interferons Phase 4,Phase 3,Phase 2,Phase 1
32 Protective Agents Phase 4,Phase 3,Phase 2
33 Radiation-Protective Agents Phase 4,Phase 2
34 Sunscreening Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
37 Antimetabolites, Antineoplastic Phase 4,Phase 3,Early Phase 1
38 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Hormone Antagonists Phase 4,Phase 2,Phase 3
40 Hormones Phase 4,Phase 2,Phase 3
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
42 Anticholesteremic Agents Phase 4,Phase 2
43 Hypolipidemic Agents Phase 4,Phase 2
44 Lipid Regulating Agents Phase 4,Phase 2
45 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
46 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
47 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
48 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
50 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 350)

# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
2 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
3 Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis Unknown status NCT01656226 Phase 4
4 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
5 Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
6 Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
7 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
8 Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
9 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
10 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
11 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT) Completed NCT01000636 Phase 4
12 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
13 Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Completed NCT02251652 Phase 4 Ingenol Mebutate
14 Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
15 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
16 Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
17 Effects of Topical Diclofenac on Tumor Metabolism Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
18 Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
19 Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine
20 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
21 Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
22 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
23 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
24 Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
25 Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients Completed NCT00599807 Phase 4
26 Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails Completed NCT01703325 Phase 4 0.1% triamcinolone , 0.05% clobetasol propionate ointment
27 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
28 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Recruiting NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
29 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Recruiting NCT02866695 Phase 4 ingenol mebutate gel 0.015%
30 Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy Active, not recruiting NCT02990221 Phase 4 Ingenol mebutate
31 IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis Active, not recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
32 Daylight-PDT With MAL for AK and Photodamaged Skin Active, not recruiting NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
33 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
34 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
35 Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
36 Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
37 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
38 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
39 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
40 Actinic Keratoses Treatment With Metvix® in Combination With Light Unknown status NCT02373371 Phase 3 Metvix®
41 T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
42 5fluorouracil for Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
43 A Study of the Clinicopathologic Behaviour of the Different Types of Unsafe Chronic Otitis Media Unknown status NCT00270660 Phase 3
44 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
45 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00942604 Phase 3 PEP005 (ingenol mebutate) Gel;Vehicle gel
46 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00742391 Phase 3 PEP005 (ingenol mebutate) Gel;Vehicle gel
47 Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment Completed NCT01459393 Phase 3 5-ALA Photodynamic Therapy;Cryotherapy with liquid nitrogen
48 Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses Completed NCT02289768 Phase 3 5-fluorouracil/salicylic acid;Vehicle
49 Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis Completed NCT02616601 Phase 3 Carac Cream;Generic Fluorouracil Cream;Placebo
50 Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities Completed NCT02137785 Phase 3 Aminolevulinic Acid (ALA);Topical Solution Vehicle

Search NIH Clinical Center for Keratosis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: keratosis

Genetic Tests for Keratosis

Anatomical Context for Keratosis

MalaCards organs/tissues related to Keratosis:

38
Skin, Testes, Kidney, T Cells, Liver, Bone, Neutrophil

Publications for Keratosis

Articles related to Keratosis:

(show top 50) (show all 1188)
# Title Authors Year
1
Melanoma in situ mimicking a Lichen planus-like keratosis. ( 29350666 )
2018
2
Actinic Keratosis and Non-Invasive Diagnostic Techniques: An Update. ( 29316678 )
2018
3
Arsenical keratosis secondary to Fowler solution. ( 29387754 )
2018
4
Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis. ( 29442526 )
2018
5
Daylight-Mediated Photodynamic Therapy With Methyl Aminolevulinate in Actinic Keratosis Treatment. ( 29351725 )
2018
6
Daylight photodynamic therapy: experience in the treatment of actinic keratosis in San Gallicano Institute of Rome and a review of literature. ( 29368865 )
2018
7
Topical formulations of delta-aminolevulinic acid for the treatment of actinic keratosis: Characterization and efficacy evaluation. ( 29407554 )
2018
8
Tracking actinic keratosis of face and scalp treated with 0.015% ingenol mebutate to identify clinical and dermoscopic predictors of treatment response. ( 29356164 )
2018
9
A multi-centre, open, investigator initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0.015% on the face and scalp, and 0.05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT). ( 29355904 )
2018
10
Self-expressed patient preferences for the treatment of actinic keratosis: results from a non-interventional study based on a real-life setting in Spain. ( 29402758 )
2018
11
Detection of human papillomavirus in actinic keratosis. ( 29383738 )
2018
12
Evaluation of T lymphocyte subpopulations in Actinic Keratosis, In Situ and Invasive Squamous Cell Carcinoma of the Skin. ( 29419888 )
2018
13
Daylight Photodynamic Therapy Versus 5-Fluorouracil for the Treatment of Actinic Keratosis: A Case Series. ( 29322431 )
2018
14
Treating actinic keratosis: assessment of effectiveness, discomfort, costs and follow-up. ( 29441544 )
2018
15
Astragalin attenuates UVB radiation-induced Actinic Keratosis formation. ( 29298652 )
2017
16
Keratosis Obturans: A Disease of the Tropics? ( 28929057 )
2017
17
Actinic keratosis modelling in mice: A translational study. ( 28662116 )
2017
18
Patient satisfaction and reported outcomes on the management of actinic keratosis. ( 28553130 )
2017
19
A case report of rare palmoplantar keratosis and nail dystrophy with imatinib. ( 28189257 )
2017
20
Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. ( 29311040 )
2017
21
Rosettes in actinic keratosis and squamous cell carcinoma: distribution, association to other dermoscopic signs and description of the rosette pattern. ( 28707711 )
2017
22
Somatic HRAS p.G12S mosaic mutation causes unilaterally distributed epidermal nevi, woolly hair and palmoplantar keratosis. ( 28295558 )
2017
23
Tobacco Pouch Keratosis in a young individual: A brief description. ( 29440796 )
2017
24
Intracapsular tonsillectomy for keratosis pharyngeous: A pilot study of postoperative recovery and surgical efficacy. ( 28931194 )
2017
25
Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients. ( 28373119 )
2017
26
In-clinic application of ingenol mebutate 0.015% gel for actinic keratosis in large areas of the face is feasible and attracts a high rate of patient satisfaction: Results of a questionnaire. ( 28776637 )
2017
27
Three cases of Nagashima-type palmoplantar keratosis associated with atopic dermatitis: A diagnostic pitfall. ( 29168226 )
2017
28
Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest. ( 28628679 )
2017
29
In vivo microvascular imaging of cutaneous actinic keratosis, Bowen's disease and squamous cell carcinoma using dynamic optical coherence tomography. ( 28502083 )
2017
30
Rare ocular manifestations in keratosis follicularis (Darier-White disease). ( 28905836 )
2017
31
Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face. ( 28628678 )
2017
32
Keratosis Follicularis Spinulosa Decalvans with Associated Mental Retardation: Response to Isotretinoin. ( 28932071 )
2017
33
Treatment of Multiple Actinic Keratosis and Field of Cancerization with Topical Piroxicam 0.8% and Sunscreen 50+ in Organ Transplant Recipients: A Series of 10 Cases. ( 29282394 )
2017
34
Evaluation of the quality of life in patients with arsenic keratosis. ( 28840749 )
2017
35
Epithelial-to-mesenchymal transition contributes to invasion in squamous cell carcinomas originated from actinic keratosis through the differentiated pathway, whereas proliferation plays a more significant role in the classical pathway. ( 28796927 )
2017
36
Reflectance confocal microscopy of an inverted follicular keratosis mimicking a squamous cell carcinoma. ( 29214108 )
2017
37
Dermoscopy of Pigmented Actinic Keratosis of the Face: A Study of 232 Cases. ( 28705516 )
2017
38
Nilotinib-induced Keratosis Pilaris Associated with Alopecia Areata and Eyebrow Thinning. ( 28839396 )
2017
39
Acantholytic squamous cell carcinoma is usually associated with hair follicles, not acantholytic actinic keratosis, and is not "high risk": Diagnosis, management, and clinical outcomes in a series of 115 cases. ( 27889291 )
2017
40
A seamless Phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp. ( 28078678 )
2017
41
Detection of Merkel Cell Polyomavirus in Seborrheic Keratosis. ( 29375515 )
2017
42
A rare presentation of keratosis follicularis spinulosa decalvans in female twins. ( 28928337 )
2017
43
Actinic keratosis. Or maybe not? ( 28556349 )
2017
44
New and current preventive treatment options in actinic keratosis. ( 28805940 )
2017
45
Three-day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: A Phase II Trial. ( 29399263 )
2017
46
A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis. ( 28805092 )
2017
47
A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity. ( 28536731 )
2017
48
Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs. ( 29296668 )
2017
49
Phasor-FLIM as a Screening Tool for the Differential Diagnosis of Actinic Keratosis, Bowen's Disease, and Basal Cell Carcinoma. ( 28661125 )
2017
50
Novel nonsense mutation in SERPINB7 and the treatment of foot odor in a patient with Nagashima-type palmoplantar keratosis. ( 28439958 )
2017

Variations for Keratosis

Expression for Keratosis

Search GEO for disease gene expression data for Keratosis.

Pathways for Keratosis

Pathways related to Keratosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.97 FGFR3 FLG IVL KRT1 KRT10 KRT17
2
Show member pathways
11.56 FLG IVL KRT1 KRT10 KRT17 KRT9
3 11.36 CDKN2A FGFR3 TP53
4 11.3 CDKN2A PIK3CA TP53
5 10.94 FGFR3 PIK3CA TP53

GO Terms for Keratosis

Cellular components related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.35 FLG KRT1 KRT10 KRT17 KRT9
2 cornified envelope GO:0001533 8.92 FLG IVL KRT1 KRT10
3 cytosol GO:0005829 10 CDKN2A FLG GJB2 IVL KRT1 KRT10

Biological processes related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 epidermis development GO:0008544 9.63 ATP2A2 KRT17 KRT9
2 aging GO:0007568 9.56 CTSC GJB2 LRP1 TP53
3 keratinization GO:0031424 9.55 IVL KRT1 KRT10 KRT17 KRT9
4 keratinocyte differentiation GO:0030216 9.5 FLG IVL KRT10
5 intermediate filament organization GO:0045109 9.48 KRT17 KRT9
6 replicative senescence GO:0090399 9.43 CDKN2A TP53
7 response to UV-B GO:0010224 9.4 IVL TP53
8 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.37 MBTPS2 TP53
9 peptide cross-linking GO:0018149 9.26 FLG IVL KRT1 KRT10
10 cornification GO:0070268 9.1 FLG IVL KRT1 KRT10 KRT17 KRT9

Molecular functions related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.35 FLG IVL KRT1 KRT10 KRT17
2 structural constituent of epidermis GO:0030280 8.8 FLG KRT1 KRT10

Sources for Keratosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....